RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%Milan, 8th May 2025 – The Board of Directors of Recordati S.p.A. approved the Group’s Interim Report as of 31st March 2025, representing additional voluntary financial reporting(7). The Report was prepared using the assessment, measurement and recognition criteria prescribed by international accounting standards (IFRS). The financial statements as of 31st March 2025 will be available by 15th May 2025 at the company’s offices and on the company’s website (www.recordati.it) and can also be viewed on the authorised storage system 1Info (www.1Info.it).
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLIONRECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROMERECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISEMilan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
